[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"synovitis-of-knee\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:synovitis-of-knee":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100597328","light-therapy-on-pain-and-synovitis-100597328",false,"NCT07057063","Light Therapy on Pain and Synovitis","Effect of Light Therapy on Pain and Synovitis in Patients With Knee Synovitis: Study Protocol for a Randomized Controlled Trial","Inclusion Criteria:\n\n* Participants aged between 40 and 80 years\n* Able to provide written informed consent\n* Have experienced knee pain that persists or recurs for more than 3 months\n* A knee pain score of at least 30 mm on the 100-mm Visual Analogue Scale (VAS) during the past week\n* Ultrasound-measured knee synovitis ≥1\n* Presence of knee OA according to criteria established by the American College of Rheumatology\n\nExclusion Criteria:\n\n* Anticipated need for knee surgery within the next one year\n* Previous or planned knee replacement within the next one year\n* Knee surgery or other physical therapy in the previous 3 months\n* Use of intra-articular, intra-muscular, or oral corticosteroids in previous 4 weeks\n* Malignant tumors or other life-threatening diseases\n* Severe mental disorders, including but not limited to schizophrenia, bipolar disorder, or major depressive disorder, that may interfere with the participant's ability to comply with the study protocol or provide informed consent","ALL","40 Years","80 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","Background: Knee pain is a common complaint among middle-aged and older adults, often leading to reduced mobility and diminished quality of life. Synovitis is a major underlying cause, present in up to 80% of individuals with moderate knee pain. While light therapy has shown anti-inflammatory and analgesic effects in preclinical studies, our prior animal experiments revealed that light therapy at 810 nm significantly alleviated inflammation and pain-like behaviors. These findings suggest a potential wavelength-specific therapeutic effects. However, it remains unclear whether such effects can be replicated in humans. This study aims to evaluate the efficacy of 810 nm light therapy, compared to sham treatment, in reducing knee pain and synovitis in patients with chronic knee pain and knee synovitis.\n\nMethods\u002Fdesign:\n\nThis is a randomized, placebo-controlled clinical trial involving 90 participants with chronic knee pain and ultrasound-detected synovitis. Participants will be randomized into two groups to receive 810 nm light therapy, or sham therapy, delivered twice weekly over five weeks. Primary outcomes include knee pain assessed by the Visual Analogue Scale (VAS) and synovitis assessed by ultrasound. Secondary outcomes include the Knee injury and Osteoarthritis Outcome Score (KOOS), the 30-second chair stand test, and the 40-meter fast-paced walk test. Outcome assessments will be performed at baseline, post-intervention (week 5), and at 1 month and 6 months after treatment completion. Linear mixed-effects models will be used to compare outcome changes between groups.\n\nDiscussion:\n\nThis trial will assess whether 810 nm light therapy provides clinically meaningful benefits for reducing knee pain and synovitis in humans, building on promising preclinical findings. Results from this study may support the use of near-infrared light as a safe, non-invasive, and effective intervention for synovitis-related knee pain.",[27,28,29],"Knee Pain Chronic","Synovitis of Knee","Light Therapy",[31,32,33,34,35,36,37],"Light therapy","Photobiomodulation","Chronic knee pain","Synovitis","Randomized controlled trial","Non-pharmacological intervention","physical therapy","RECRUITING","2025-11-19",{"date":41,"type":42},"2025-11-26","ACTUAL",{"date":44,"type":42},"2025-07-13",{"date":46,"type":21},"2026-05-28",{"name":48,"class":49},"The Hong Kong Polytechnic University","OTHER",2,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100605347","phase-2-role-of-methotrexate-in-ultrasound-proven-synovitis-in-primary-knee-oa-100605347","NCT07161336","Role of Methotrexate in Ultrasound Proven Synovitis in Primary Knee OA","Role of Methotrexate in Ultrasound Proven Synovitis in Patients With Knee Osteoarthritis : A Randomized Controlled Trial","MTX in knee OA","Inclusion Criteria:\n\n* Men and women aged between 40 to 70 years\n* Patients fulfilling American College of Rheumatology (ACR) clinical and radiological criteria for knee OA. (knee pain + at least 3 of 5 that not including \"no palpable warmth\")\n* Knee pain on most days for at least 6 months, with a pain VAS of at least 40mm\n* Radiological grading of OA with Kallgren-Lawrence grade of 2 to 3\n* Patients with the presence of knee synovitis in Musculoskeletal ultrasound\n\nExclusion Criteria:\n\n* Any known inflammatory arthritis\n* BMI \\>= 40 kg\u002Fm2\n* Abnormal renal (e.g. abnormal renal function Creatinine clearance \\\u003C35 ml) hepatic (including active hepatitis B, hepatitis C, abnormal liver function), hematological (e.g. white cell count \\\u003C 4 × 109\u002FL, platelets \\\u003C100 ×109\u002FL, or hemoglobin \\\u003C 9 g\u002FdL), function\n* Use of intra-articular, intramuscular or oral corticosteroids in previous 4 weeks\n* History knee joint surgery, Charcot joint\n* Severe valgus knee deformity (angle of genu valgum \\> 30°)\n* Use of any disease modifying agents (e.g. hydroxychloroquine or sulfasalazine) in previous 3 months\n* Allergic to MTX\n* Pregnant or lactating women","70 Years",{"count":61,"type":21},70,[63],"PHASE2","Background:\n\nOsteoarthritis (OA) is a leading cause of disability worldwide, with limited treatment options and many patients suffering from chronic pain. Modern imaging has revealed that OA involves complex changes in cartilage, subchondral bone, and synovium. Pain in OA is often linked to synovitis, which is common in the condition. Methotrexate (MTX), a proven treatment for synovitis in inflammatory arthritis like rheumatoid arthritis and has a well-known safety profile. The proposal suggests that using MTX may have potential to treat symptomatic knee OA with USG (musculoskeletal ultrasound) proven synovitis by reducing synovitis and as a result, alleviate pain.\n\nObjectives:\n\nTo assess the role of methotrexate in primary knee osteoarthritis associated with ultrasound proven synovitis.\n\nMethods:\n\nThis randomized Controlled trial will be conducted in the department of Rheumatology, Bangladesh Medical University (BMU) from July 2025 to June 2026. A total of 70 patients will be enrolled with primary knee OA diagnosed on the basis of ACR Criteria for Knee OA with informed written consent. MSK USG examinations of knee joint and scoring (OMERACT SCORE) will be performed to detect synovitis by a rheumatologist expert in MSK US. Then randomization will be done into group A and group B following a randomization table, each consisting of 35 patients. Consecutive sampling techniques will be followed. One group will receive MTX (start with 15 mg per week for the first 2 weeks then increase to 20 mg and continue for the remaining period if tolerated) and Both groups of patients will be allowed to take NSAIDs on a requirement basis with documentation and follow non-pharmacological treatment of OA. At the end of 3rd and 6th month pain and functional status will be assessed by WOMAC, VAS and quality of life will be assessed by using Bangla version of SF-12. At the end of 6th month improvement of synovitis will be seen by MSK USG of involved knees with OMERACT scoring. Primary endpoint for efficacy will be assessed at the end of 24th week by WOMAC. Secondary endpoints will be determined by VAS and SF-12. Adverse effects will be assessed by history, physical examinations and investigations. The data will be analyzed by using the latest version SPSS software (Version 29). Results will be recorded using means and standard deviations. Results will be compared among two groups with a 95% confidence interval and a p- value of \\\u003C 0.05 will be considered statistically significant. The degrees of statistical significance between groups will be analyzed by unpaired t test (for quantitative normally distributed data) and Mann Whitney U test if there is skewed distribution. Qualitative data in between groups will be analyzed by the chi square test. Probabilities of associations will be assessed by calculating Pearson's rank correlation coefficient. P-value \\\u003C0.05 will be regarded as statistically significant. The nature, purpose and implication of the study as well as the entire spectrum of benefits and risks of study will be explained to the patients. Privacy and confidentiality of the subject will be maintained. Each patient will enjoy the right to participate and or withdraw from the study at any point of the study period. Ethical clearance will be obtained from the institutional Review Board (IRB) of BMU.",[66,28,67],"Osteo Arthritis of the Knee","Methotrexate",[69,70,67],"knee OA","synovitis","2025-09-07",{"date":73,"type":42},"2025-09-12",{"date":75,"type":42},"2025-07-30",{"date":77,"type":21},"2026-08-30",{"name":79,"class":49},"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":18,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":100,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":80},"100493094","perfusion-mri-targeted-joint-embolization-for-chronic-musculoskeletal-pain-of-the-shoulder-hip-and-knee-100493094","NCT05700682","Perfusion MRI-targeted Joint Embolization for Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee","Perfusion MRI-targeted Joint Embolization to Diagnose and Treat Neovascularity Associated With Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee: A Prospective Cohort Study","MRI","Inclusion Criteria (Both Arms):\n\n1. Participants must be Veterans who receive care in the VA system.\n2. Participants must have a history of chronic pain of the shoulder, hip or knee for at least 1 year.\n3. Participants must have mild to moderate degenerative changes of the painful joint as depicted on prior imaging (X-ray, CT or MRI).\n4. Participants must have undergone at least one failed primary treatment for their chronic pain (e.g. physical therapy, NSAIDs, steroid injection).\n5. Participants must have an MRI of their painful joint (shoulder, hip or knee) ordered by a clinical provider.\n\nInclusion Criteria (Therapeutic Arm):\n\n1. Participants must have enrolled in the Diagnostic Arm of the study and must have undergone perfusion MR imaging of their painful joint.\n2. Participants must have evidence of peri-articular hypervascularity on their perfusion MR exams. This will be determined by the study PIs.\n\nExclusion Criteria (Diagnostic Arm):\n\n1. Acute injury in the last 12 weeks.\n2. Age under 25.\n3. Severe degenerative changes of painful joint (shoulder, hip or knee).\n4. History of arthroplasty or metallic implant within the painful joint.\n5. Severe gadolinium contrast allergy.\n6. Severe renal disease or ongoing dialysis.\n7. History of malignancy with life expectancy of less than one year, or malignancy with known bone metastasis.\n8. Current pregnancy.\n9. Formal diagnosis of cognitive impairment.\n\nExclusion Criteria (Therapeutic Arm):\n\n1. Severe iodinated contrast allergy.\n2. Severe coronary or peripheral arterial disease.\n3. Coagulopathy.\n4. Uncontrolled type 2 diabetes or diabetic neuropathy.\n5. History of seizures or other severe complication from conscious sedation.\n6. Prior upper or lower extremity arterial bypass.\n7. Ongoing participation in another interventional (therapeutic) trial for chronic joint pain.\n8. Lack of peri-articular hypervascularity on initial perfusion MRI.\n9. All exclusion criteria for the Diagnostic Arm.","25 Years",{"count":91,"type":21},120,"OBSERVATIONAL","In this work the investigators will study the relationship between chronic musculoskeletal pain and abnormal blood flow (neovascularity) around the shoulder, hip and knee. Veterans with as history of chronic shoulder, hip or knee pain and mild\u002Fmoderate joint degenerative changes will be potential study subjects. Blood flow around joints will be evaluated using perfusion magnetic resonance imaging (MRI). Participants with demonstrably abnormal blood flow around their painful joint will be eligible for enrollment in a pilot study of joint embolization to treat their pain. Participants who choose to not undergo treatment will be re-assessed with MRI after one year to characterize the natural history of joint neovascularity and its relationship to pain.",[95,96,97,28,98,34,99],"Osteoarthritis, Knee","Osteoarthritis, Hip","Osteo Arthritis Shoulders","Synovitis\u002FTenosynovitis - Hip","Pain, Chronic",[101,102,103,104,105,106,107],"joint","embolization","neovascularity","pain","knee","hip","shoulder","2025-08-04",{"date":110,"type":42},"2025-08-07",{"date":112,"type":42},"2023-07-15",{"date":114,"type":21},"2026-08-01",{"name":116,"class":49},"Palo Alto Veterans Institute for Research"]